Ticagrelor versus clopidogrel in orally anticoagulated patients with acute coronary syndrome undergoing percutaneous coronary intervention
EuroIntervention · 2026
DOI: 10.4244/eij-d-25-01373 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift EuroIntervention, 2026. Verfasst von Oskar Love Emilsson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden. Hauptthemen laut MEDLINE: Ticagrelor, Clopidogrel, Acute Coronary Syndrome, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: In patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and who are treated with direct oral anticoagulants (DOACs), dual antithrombotic treatment without aspirin is recommended. Evidence comparing P2Y12 inhibitor strategies in this setting is limited. AIMS: This study aimed to compare outcomes with ticagrelor versus clopidogrel as part of dual antithrombotic treatment in ACS patients undergoing PCI. METHODS: Using data from the SWEDEHEART registry, we conducted a cohort study including patients on dual antithrombotic treatment with ACS undergoing PCI between January 2014 and February 2022. Outcomes within one year were analysed using multivariate Cox regression to obtain adjusted hazard ratios (aHR) with 95% confidence intervals (CI) for major adverse cardiovascular events (MACE; including mortality, myocardial infarction [MI], and stroke), all-cause mortality, clinically relevant bleeding, and MI. RESULTS: A total of 3,708 patients were included (median age 76 years; 69% males; 40% ST-segment elevation myocardial infarction). At discharge, 1,170 (32%) received ticagrelor and 2,538 (68%) clopidogrel. For MACE, the unadjusted event rate was 16.7% in the ticagrelor group and 16.6% in the clopidogrel group (aHR 1.02, 95% CI: 0.84-1.23). Mortality occurred in 6.6% of patients treated with ticagrelor and 6.2% of those treated with clopidogrel (aHR 1.24, 95% CI: 0.91-1.69). Bleeding was 4.9% in the ticagrelor group compared with 3.7% in the clopidogrel group (aHR 1.53, 95% CI: 1.06-2.22). MI occurred in 10.4% of patients on ticagrelor and 11.2% of those on clopidogrel (aHR 0.90, 95% CI: 0.71-1.13). CONCLUSIONS: In ACS patients on DOACs undergoing PCI, ticagrelor was associated with an increased risk of bleeding compared with clopidogrel, with no differences in MACE, mortality, or MI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden.
- Department of Thoracic Surgery and Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden and Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
- Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden.
Zitieren
APA
Emilsson, O. L., Mohammad, M. A., van der Pals, J., Braun, O., Angerås, O., Jernberg, T., Zhou, M., von Koch, S., Erlinge, D., & Koul, S. (2026). Ticagrelor versus clopidogrel in orally anticoagulated patients with acute coronary syndrome undergoing percutaneous coronary intervention. EuroIntervention. https://doi.org/10.4244/eij-d-25-01373
Vancouver
Emilsson OL, Mohammad MA, van der Pals J, Braun O, Angerås O, Jernberg T, et al. Ticagrelor versus clopidogrel in orally anticoagulated patients with acute coronary syndrome undergoing percutaneous coronary intervention. EuroIntervention. 2026. doi:10.4244/eij-d-25-01373
BibTeX
@article{Emilsson2026,
author = {Emilsson, Oskar Love and Mohammad, Moman A and van der Pals, Jesper and Braun, Oscar and Angerås, Oskar and Jernberg, Tomas and Zhou, Mikael and von Koch, Sacharias and Erlinge, David and Koul, Sasha},
title = {Ticagrelor versus clopidogrel in orally anticoagulated patients with acute coronary syndrome undergoing percutaneous coronary intervention},
journal = {EuroIntervention},
year = {2026},
doi = {10.4244/eij-d-25-01373}
}
EUVIMED